MAVENIR
30.9.2021 15:02:04 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced its next-generation Operations Support System (ngOSS) , a new addition to the MAVscale platform.
The new solution brings together a powerful combination of Artificial Intelligence (AI), Analytics, Automation, and Orchestration, backed by Mavenir’s experience delivering telecom network solutions to allow Communication Service Providers (CSPs) to deploy ngOSS in their 4G networks today, while at the same time preparing to fully realize the potential of 5G capabilities through intelligent network operations.
By enhancing network performance, Mavenir’s ngOSS enables CSPs to improve the overall customer experience, lower operating expenses (OPEX), and reduce the risk of manual errors more prevalent in legacy OSS systems.
The end-to-end, cloud-native automation framework is built based on TM Forum’s Open Digital Architecture (ODA) and OpenAPIs that uses enhanced AI and Machine Learning (ML) models to deliver advanced network performance. Engineered with a microservices-based architecture, Mavenir's ngOSS solution simplifies large, legacy, monolithic systems into smaller, autonomous components that offer intelligence, insights, and network control. A more open, automated network is necessary to break legacy vendor lock-in while driving innovation for 5G use cases.
Mavenir is an OSS vendor with 4G/5G and mobile core/Radio Access Network (RAN) expertise, and in-depth understanding of orchestrating telecommunications workloads required for enabling advanced 5G capabilities, including network slicing, which translates directly into efficiencies for the CSPs.
“As CSPs advance toward automation, next-generation OSS will be a critical component to enable the network of the future,” said Kuntal Chowdhury, SVP and GM of AI and Analytics at Mavenir. “Using advanced AI and ML models to enhance network performance will help CSPs deliver superior customer experience, while scalable automation reduces manual tasks to lower maintenance costs and reduces the risk of human error. Mavenir’s ngOSS solution allows CSPs to break open the network and take advantage of Open APIs to increase agility and innovation, introduce new services, and monetize 5G with rapid service velocity.”
Key capabilities of Mavenir’s ngOSS include:
- Service Fulfillment and Orchestration – Service Order Management integrates with the Business Support System (BSS) layer using Open APIs to deliver dynamic order creation, support complex workflow creation, and offer complete visibility & management into service order execution. Service Orchestration provides a complete network automation solution, including Service Design, 5G Slice Management, and Network Service Orchestration.
- Data Management – Mavenir’s Provisioning and Activation function is radically different from the traditional provisioning offerings from legacy vendors. It elevates provisioning to a whole new level by offering Provisioning-as-a-Service on any cloud, from any vendor, on any domain approach. In addition, Mavenir’s Active Inventory collects, maintains, and exposes a federated real-time view of available network resources and services from across multiple cloud and vendor environments.
- Service Assurance and AI Operations (AIOps) – Mavenir Service Assurance and AIOps platform addresses CSP’s operational challenges by providing end-to-end visibility into the network, enabling an open network by integrating with any cloud, any vendor, and any technology domain, and performing critical AIOps functions, such as AI-driven predictive alarm correlation, ML-assisted Ticket Analysis, and auto Root Cause Analysis (RCA), resulting in increased productivity, shorter Mean Time To Repair (MTTR), and OPEX savings.
- Domain Controllers – Mavenir’s Non-Real-Time RAN Intelligent Controller (RIC) is a containerized application that uses advanced machine learning algorithms to optimize RAN performance and train ML models using long term RAN data for dynamic and adaptive policy and control. Mavenir’s Network Subnet Slice Management Function (NSSMF) is an open, cloud-native, and vendor-agnostic function that plays a crucial role in 5G slice management as it does the last-mile connections necessary to configure a slice.
Supporting documents:
Mavenir ngOSS webpage
Mavenir ngOSS solution brief
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005144/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
